| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Better Choice Company (NYSE:BTTR) ("Better Choice" or the "Company"), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets. The MOU sets out the basis for Dr. Crosignani to commence research and development of a GLP1 supplement for use in companion animals. Combining a GLP1 supplement with Better Choices' Halo branded toppers or treats for dogs and cats to treat obesity and other health issues associated with overweight pets is an area of growing interest as more than half of dogs and cats worldwide are classified as overweight or obese.
Dr. Crosignani is a leading international researcher in pet health and a professor of Veterinary Science at the Universidad de la Republic de Uruguay operating in the department of Pharmacology in the Faculty of Veterinary Medicine. Dr. Crosignani holds a MS in Physiology from the University of Rio Grande do Sul, UFRGS, Brazil and a PhD in Anesthesia from the Faculty of Medicine, University of Sao Paulo, UNESP, Brazil. In addition, Dr. Crosignani has a post-doctorate degree from UNESP, Faculty of Medicine, researching in the field of pain management.
"We are pleased to make progress with our R&D partners, APH and Dr. Crosignani. We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help Better Choice and our brands, including Halo, become pioneers in this sector," commented Mike Young, Chairman of the Board for Better Choice.
Posted In: BTTR
